State of Alaska Department of Revenue’s ADC Therapeutics ADCT Stock Holding History

State of Alaska Department of Revenue’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32K	Buy	+30,000	New	+$87.5K	﹤0.01%	1997

Other funds holding ADCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SCTC

Sanibel Captiva Trust Company Sanibel, Florida $4.02B AUM 34.36% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State of Alaska Department of Revenue's ADCT Position: Q2 2026 in Review

State of Alaska Department of Revenue opened a new position in ADC Therapeutics (ADCT) in Q2 2026: 30,000 shares worth $32K. The stake represents ﹤0.01% of the portfolio and ranks #1997 among its holdings.

59 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

State of Alaska Department of Revenue held 30,000 shares of ADC Therapeutics worth $32K as of Q2 2026.
ADC Therapeutics was a new State of Alaska Department of Revenue position in Q2 2026.
ADC Therapeutics made up ﹤0.01% of State of Alaska Department of Revenue's portfolio in Q2 2026, its #1997 holding.
59 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on State of Alaska Department of Revenue's 13F filing for Q2 2026, filed 20 Jul 2026.